skip to content

The PAN-cancer study is a collaboration between Owlstone Medical Ltd, Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge Cancer Research UK Cambridge Centre. The study is a prospective, cross-sectional observational case-control trial evaluating whether Owlstone Medical’s Breath Biopsy® technology can differentiate between patients with and without different cancer types by comparing breath biomarkers in gastric, oesophageal, renal, prostate, bladder, liver and pancreatic cancer. This study is the first step in evaluating volatile organic compounds analysis as a test to improve early detection rates for cancer with future applicability to primary care. Further information can be found here: